Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Serotonin Syndrome 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Dumping Syndrome 1Congenital Hyperinsulinism 1Carcinoma, Neuroendocrine 1Carcinoma 1Adrenocortical Hyperfunction 1Adenoma, Islet Cell 1ACTH Syndrome, Ectopic 1

Interventions

pasireotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Growth Disorders × pasireotide × Endocrine × Clear all
NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡